WP
LABP

Woodline Partners’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Woodline Partners’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,280
Closed -$3.11M – 835
2021
Q3 		$3.11M Sell
21,280
-54
-0.3% -$7.01K 0.05% 332
2021
Q2 		$2.46M Hold
21,334
– – 0.05% 320
2021
Q1 		$2.05M Buy
+21,334
New +$2.78M 0.05% 284

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners's LABP Position: Q4 2021 in Review

Woodline Partners sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2021, closing a stake of 21,280 shares — an estimated $3.11M sold.

Woodline Partners first reported a position in LABP in Q1 2021 and held it in 3 quarters. The position peaked at $3.11M in Q3 2021. 40 funds tracked by Wall St. Rank hold LABP as of Q4 2021.

  • Woodline Partners reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Woodline Partners sold 21,280 Landos Biopharma, Inc. Common Stock shares in Q4 2021, an estimated $3.11M.
  • Woodline Partners first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Woodline Partners's Landos Biopharma, Inc. Common Stock position peaked at $3.11M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.